The Phase IIb POWER 1 and 2 trials compared the efficacy and safety of darunavir plus low-dose ritonavir (darunavir/ritonavir) with currently available PIs in highly treatment-experienced patients ...
The third pivotal study in treatment-naive patients compared dolutegravir to the DHHS guideline recommended boosted protease inhibitor darunavir/ritonavir. The FLAMINGO study is a 96-week ...